About three million people globally are ‘missed’ each year for Tuberculosis diagnosis. Many of them will die, some will get better, others will continue to infect others.
Articles on XDR-TB
Displaying all articles
To tackle TB a dynamic change in discourse is needed. The focus must be on how to respond to emerging complexities the disease presents.
Antibiotics that were not originally earmarked to treat TB have shown the first signs of effectiveness and could be added to the much-needed arsenal of drugs to fight the deadly disease.
South African scientists have found a way to single out the problematic parts of the bacteria causing TB that results in drug resistance.
There is an increasing focus on alternative treatment strategies, developed to treat other diseases and conditions but re-purposed to tackle TB.
Top contributors
-
Faculty Member, Africa Health Research Institute; Associate professor, UCL
-
Scientist with the Division of Molecular Biology and Human Genetics and Director of TASK Applied Science, Stellenbosch University
-
Head of the Division of Pulmonology, University of Cape Town
-
Associate Professor, SARChI Research Chair in Mycobactomics, Stellenbosch University
-
Postdoctoral research fellow in the MRC Centre for Tuberculosis Research, Stellenbosch University
-
Public Health Specialist, Senior Research Scientist, Kenya Medical Research Institute